neobookRx
GuidelinesOther guideline

References

This guideline provides an overview of the recommended Adult ADHD assessment steps, differentials to be considered and options for treatment according to the best available evidence based guidelines.

  1. Cadell T, Davies W, Crichton A. An inquiry into the nature and origin of mental derangement: On attention and its diseases. J Atten Disord. 2008;12(3):200–204. https://doi.org/10.1177/1087054708315137
  2. Hoffmann H. Lebenserinnerungen. In: Herzog CH, Siefert H, editors. Gesammelte werke. Frankfurt, 1985.
  3. Hectman L. Attention-deficit disorders. In: Sadock BJ, Sadock VG, editors. Comprehensive textbook of psychiatry. 8th ed. Philadelphia, PN: Lippincott William & Wilkens, 2005; p. 3183–3204.
  4. Goldstein S. Managing attention and learning disorders in late adolescence and adulthood. New York: Wiley; 1997.
  5. Reimherr FW, Hedges DW, Strong RE, Wender PH. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Presented at: The 35th Annual Meeting to the New Clinical Drug Evaluation Unit Program; 1995 May 1– Jun 3; Orlando, FL.
  6. National Resource Centre on AD/HD. Statistical prevalence of ADHD [homepage on the Internet]. c2013 [cited 2013 Mar 10]. Available from http://www. help4adhd.org/en/about/statistics
  7. Wittchen H, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679. https://doi.org/10.1016/j.euroneuro.2011.07.018
  8. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–165. https://doi.org/10.1017/S003329170500471X 
  9. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–409. https://doi.org/10.1192/bjp.bp.106.034389
  10. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. https://doi.org/10.1176/ajp.2006.163.4.716
  11. Simon V, Czobor P, Balint A, et al. Prevalence and correlates of adult attentiondeficit hyperactivity disorder: Meta-analysis. Br J Psychiatry. 2009;194:204–211. https://doi.org/10.1192/bjp.bp.107.048827
  12. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335–342. https://doi.org/10.1177/ 1087054707299597
  13. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/ hyperactivity disorder in children: Incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188–203. https://doi.org/10.1016/j. clinthera.2011.03.001
  14. Matte B, Anselmi L, Salum GA, et al. ADHD in DSM-5: A field trial in a large, representative sample of 18- to 19-year-old adults. Psychol Med. 2015;45(2):361–373. https://doi.org/10.1017/S0033291714001470
  15. McLean A, Dowson J, Toone B, et al. Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psychol Med. 2014;34(4):681–692. https://doi.org/10.1017/S0033291703001296
  16. Van de Voort JL, He JP, Jameson ND, Merikangas KR. Impact of the DSM-5 attention-deficit/hyperactivity disorder age-of-onset criterion in the US adolescent population. J Am Acad Child Adolesc Psychiatry. 2014;53(7):736–744. https://doi.org/10.1016/j.jaac.2014.03.005
  17. Stein DJ, Williams DR, Kessler RC. The South African Stress and Health (SASH) study: A scientific base for mental health policy. S Afr Med J. 2009;99(5):337–344.
  18. Abramovitch A, Goldzweig G, Schweiger A. Correlates of physical activity with intrusive thoughts, worry and impulsivity in adults with attention deficit/ hyperactivity disorder: A cross-sectional pilot study. Isr J Psychiatry Relat Sci. 2013;50:47–54.
  19. Schoeman R. A funding model proposal for private health insurance for adult attention deficit/hyperactivity disorder in the South African context [Unpublished thesis in partial fulfilment for the degree Masters in Business Administration]. University of Stellenbosch; 2015.
  20. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223. https:// doi.org/10.1016/S0140-6736(12)61689-4
  21. Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatr Serv. 2005;56(12):1593–1599. https://doi.org/10.1176/appi.ps.56.12.1593
  22. Polanczyk G, De Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and meta-regression analysis. Am J Psychiatry. 2007;164(6): 942–946. https://doi.org/10.1176/ajp.2007.164.6.942
  23. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. PharmacoEconomics. 2005;23(1):93– 102. https://doi.org/10.2165/00019053-200523010-00008
  24. Kupper T, Haavik J, Drexler H, et al. The negative impact of attention-deficit/ hyperactivity disorder on occupational health in adults and adolescents. Int Arch Occup Environ Health. 2012;85(8):837–847. https://doi.org/10.1007/s00420- 012-0794-0
  25. Barkley R, Murphy KR, Fischer M. ADHD in adults: What the science says. New York: Guilford Press; 2007.
  26. Bolea B, Adamou M, Arif M, et al. ADHD matures: Time for practitioners to do the same? J Psychopharmacol. 2012;6(6):766–770. https://doi.org/10.1177/ 0269881111410898
  27. De Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: Results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65(12):835–842. https://doi.org/10.1136/oem.2007.038448
  28. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: Excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195–206. https://doi. org/10.1185/030079904X20303
  29. Kleinman NL, Durkin M, Melkonian A, Mrkosyan K. Incremental employee health benefit costs, absence days, and turnover among employees with ADHD and among employees with children with ADHD. J Occup Environ Med. 2009;51(11):1247–1255. https://doi.org/10.1097/JOM.0b013e3181bca68c
  30. Kessler RC, Lane M, Stang PE, Van Brunt DL. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2009;39(1):137–147. https://doi.org/ 10.1017/S0033291708003309
  31. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565–572. https://doi. org/10.1097/01.jom.0000166863.33541.39
  32. . Asherson P, Akehurst R, Kooij JJ, et al. Under diagnosis of adult ADHD: Cultural influences and societal burden. J Atten Disord. 2012; 16(5 Suppl):20S–38S. https://doi.org/10.1177/1087054711435360
  33. Barkley RA. Global issues related to the impact of untreated attention-deficit/ hyperactivity disorder from childhood to young adulthood. Postgrad Med. 2008;120(3):48–59. https://doi.org/10.3810/pgm.2008.09.1907 
  34. Biederman J. Breaking news: The social and economic impact of ADHD. Paper presented at: The Attention Deficit Hyperactive Disorder (ADHD) AMA Briefing; Sep 9; Manhattan, New York; 2004.
  35. Brook JS, Brook DW, Zhang C, et al. Adolescent ADHD and adult physical and mental health, work performance, and financial stress. Pediatrics. 2013; 131(1):5–13. https://doi.org/10.1542/peds.2012-1725
  36. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 5th edition [homepage on the Internet]. c2013 [cited 2013 Mar 13]. Available from http://www.dsm5.org
  37. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults [homepage on the Internet]. c2013 [cited 2013 Jun 24]. Available from http://www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf
  38. Kessler RC, Adler L, Ames M, et al. The World Health Organization adult ADHD ­self-report scale (ASRS): A short screening scale for use in the general population. Psychol Med. 2005;35(2):245–256. https://doi.org/10.1017/ S0033291704002892
  39. Barkley RA. Barkley Functional Impairment Scale (BFIS for adults). New York: Guilford Press; 2011.
  40. Brown TE. Brown attention-deficit disorders scales, manual. San Antonio, TX: Psychological Corporation; 1996.
  41. DuPaul GJ, Power TJ, Anastoloulus AD, Reid R. ADHD rating scale-IV: Checklists, norms and clinical interpretation. New York: Guilford Press; 1998.
  42. Conners CK, Erhart D, Sparrow E. Conner’s adult ADHD rating scales, technical manual. New York: Multi-Health Systems; 1999.
  43. Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: An aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(6):885–890.
  44. Marchant BK, Reimherr FW, Wender PH, Gift TE. Psychometric properties of the self-Report Wender-Reimherr adult attention-deficit disorder scale. Ann Clin Psychiatry. 2015;27(4):267–277.
  45. Epstein JN, Johnson DE, Conners CK. CAADID: The Conner’s adult ADHD diagnostic interview for DSM-IV. North Tonawanda, NY: Multi-Health Systems Inc; 2001.
  46. Kooij SJJ, Francken MH. Diagnostic interview for ADHD in adults (DIVA 2.0). Netherlands: DIVA foundation; 2010.
  47. Weiss MD, Dickson R, Wasdell M, et al. Weiss Functional Impairment Rating ScaleParent Report (WFIRS-P). Presented at: American Psychiatric Association 158th Annual Meeting; 2005 May 21–26; Atlanta, GA.
  48. Breda V, Luiz Rovaris D, Vitola ES, et al. Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample. Aust N Z J Psychiatry. 2015;50(6):557–565.
  49. Dvorsky MR, Langberg JM, Molitor SJ, Bourchtein E. Clinical utility and predictive validity of parent and college student symptoms ratings in predicting an ADHD diagnosis. J Clin Psychol. 2016;72(4):401–418. https://doi.org/10.1002/ jclp.22268
  50. Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179–203. https://doi. org/10.1177/0269881113519509
  51. Boonstra AM, Oosterlaan J, Sergeant JA, Buitelaar JK. Executive functioning in adult ADHD: A meta-analytic review. Psychol Med. 2005;35(8):1097–1108. https://doi.org/10.1017/S003329170500499X
  52. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5(4):525–539. https://doi. org/10.1586/14737175.5.4.525
  53. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1):10–41. https://doi. org/10.1177/0269881106073219
  54. Sonuga-Barke EJ, Sergeant JA, Nigg J, et al. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: Nosologic and diagnostic implications. Child Adolesc Psychiatr Clin N Am. 2008;17:367–384. https://doi. org/10.1016/j.chc.2007.11.008
  55. Knagenhjelm P, Ulberstad F. Qb test technical manual. Stockholm, Sweden: Qbtech au-Main: Insel; 2010.
  56. Berger I, Goldzweig G. Objective measures of attention-deficit/hyperactivity disorder – A pilot study. Isr Med Assoc J. 2010;12:531–535.
  57. Leark RA, Greenberg LM, Kindschi CL, et al. T.O.V.A. Professional manual test of variables of attention continuous performance test. Los Alamitos, CA: The TOVA Company; 2007.
  58. Marshall PS, Hoelzle JB, Heyerdahl D, Nelson NW. The impact of failing to identify suspect effort in patients undergoing adult attention deficit/hyperactivity disorder (ADHD) assessment. Psychol Assess. 2016;28(10):1289. https://doi. org/10.1037/pas0000247
  59. World Health Organization. Mental health [homepage on the Internet]. 2014 [cited 2014 Aug 2]. Available from: http://www.who.int/features/factfiles/ mental_health/en/
  60. Taylor D, Paton C, Kapur S. Attention deficit hyperactivity disorder. In: Taylor D, Paton C, Kapur S, editors. The Maudsley prescribing guidelines. Vol. 10. London: Informa Health, 2009; p. 263–265. https://doi.org/10.3109/ 9780203092835 
  61. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
  62. Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005;162(9):1628‒1636. https://doi.org/10.1176/appi.ajp.162.9.1628
  63. Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: A systematic literature review. CNS Drugs. 2012;26(7):581–600. https://doi.org/10.2165/11633900-000000000- 00000
  64. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry. 1937;94:577–585. https://doi.org/10.1176/ajp.94.3.577
  65. Conners C, Eisenberg L, Barcai A. Effect of dextroamphetamine on children: Studies on subjects with learning disabilities and school behavior problems. Arch Gen Psychiatry. 1967;17(4):478–485. https://doi.org/10.1001/archpsyc.1967. 01730280094011
  66. Heal DJ, Smith SL, Findling RL. ADHD: Current and future therapeutics. Curr Top Behav Neurosci. 2012;9:361–390. https://doi.org/10.1007/7854_2011_125
  67. Kooij SJJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67. https://doi.org/10.1186/1471-244X-10-67
  68. Wilens TE, Spencer MD, Biederman MD. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002; 5(4):189–202. https://doi.org/10.1177/108705470100500401
  69. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24–29. https://doi.org/10.1097/01.jcp. 0000108984.11879.95
  70. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis. CNS Drugs. 2011;25(2):157–169. https://doi.org/10.1097/01.jcp.0000108984. 11879.95
  71. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: A systematic review and indirect comparison meta-analysis. Psychopharmacology. 2008;197(1):1–11. https://doi.org/10.1007/s00213-007-0996-4
  72. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. Toronto: CADDRA; 2011.
  73. Spencer T, Wilens TE, Biederman J, Faraone SV, Ablon JS, Lapey K. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434–443. https://doi.org/10.1001/archpsyc.1995.03950180020004
  74. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–327. https://doi.org/10.2147/NDT.S9749
  75. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attentiondeficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373. https:// doi.org/10.4088/JCP.v69n0903
  76. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395–405. https://doi.org/10.1016/j. jaac.2011.01.007
  77. Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of Lisdexamphetamine Dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectrum. 2009;14:573–585. https://doi.org/10.1017/ S1092852900024056
  78. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427. https://doi.org/10.1177/0269881109103113
  79. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–364. https://doi.org/10.1007/s00787-009-0054-3
  80. Bushe CJ, Savill N. Atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder. Systematic review of review papers 2009–2011. An update for clinicians. J Cent Nerv Syst Dis. 2011;3:3209–3217. https://doi.org/10.4137/ jcnsd.s4391
  81. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112–120. https://doi.org/10.1016/S0006-3223(02)01671-2
  82. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;40(3):307–314. https://doi.org/10.1097/00004583- 199912000-00017
  83. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–1074. https://doi.org/10.1176/appi. ajp.158.7.1067
  84. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebocontrolled study of Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:73–84. https://doi. org/10.1542/peds.2006-3695
  85. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):23–228. https://doi.org/10.1097/00004714- 200104000-00015 
  86. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attentiondeficity/hyperactivity disorder in adults. Expert Rev Neurother. 2011;11(10):1443– 1465. https://doi.org/10.1586/ern.11.137
  87. Kahbazi M, Ghoreishi A, Rashiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of Modafanil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatr Res. 2009;16:234–237. https://doi.org/10.1016/j. psychres.2008.06.024
  88. Arnold VK, Feifel D, Earl CG, Yang R, Adler LA. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2012;18(2):133–144.
  89. Cephalon. Cephalon reports no benefit from Provigil in study of adults with ADHD. West Chester, PA: Cephalon; 2000.
  90. Adler LA, Resnick S, Kunz M, Devinsky O. Open label trial of venlafaxine in adult with attention deficit disorder. Psychopharmacol Bull. 1995;31:7985–788.
  91. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-defcit/hyperactivity disorder. J Clin Psychiatr. 1996;57(5):1147–1153.
  92. Conners K, Casat C, Gualtieri T, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1314– 1321. https://doi.org/10.1097/00004583-199610000-00018
  93. Wilens T, Prince J, Biederman J, et al. An open study of sustained-release bupropion in adults with ADHD and substance use disorders. Presented at: The 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu, HI.
  94. Wilens T, Haight BR, Horrigan JP, et al. Bupropion XL in adults with ADHD: A randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793–801. https://doi.org/10.1016/j.biopsych.2005.01.027
  95. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. Bupropion SR in adults with ADHD: A short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1(3):245–251.
  96. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: Meta-analysis of randomized, placebocontrolled trials. Psychiatry Clin Neurosci. 2011;65(7):611–617. https://doi. org/10.1111/j.1440-1819.2011.02264.x
  97. Wender PH, Wood DR, Reimherr FW, Ward M. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res. 1983;9:329– 226. https://doi.org/10.1016/0165-1781(83)90006-9
  98. Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder residual type in adults. Psychopharmacol Bull. 1985;21:222–230.
  99. Ernst M. MAOI treatment of adult ADHD. Paper presented at: The NIMH Conference on Alternative Pharmacology of ADHD; Washington, DC: National Institute of Mental Health (NIMH); 1996.
  100. Ernst M, Liebenauer L, Jons P, et al. Selegiline in adults with attention deficit hyperactivity disorder: Clinical efficacy and safety. Psychopharmacol Bull. 1996;32:327–344.
  101. . MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56:1073–1086. https:// doi.org/10.1001/archpsyc.56.12.1073
  102. Saffren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J, et al. Cognitive-behavioural therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43:831–842. https://doi. org/10.1016/j.brat.2004.07.001
  103. Young S, Khondoker M, Emilsson B, et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and comorbid psychopathology: A randomized controlled trial using multi-level analysis. Psychol Med. 2015;45(13):2793–2804. https://doi.org/10.1017/ S0033291715000756
  104. Philipsen A, Jans T, Graf E, et al. Effects of group psychotherapy, individual counselling, methylphenidate, and placebo in the treatment of adult attentiondeficit/hyperactivity disorder: A randomized clinical trial. JAMA Psychiatry. 2015;72(12):1199–1210. https://doi.org/10.1001/jamapsychiatry.2015.2146
  105. Bueno VF, Kozasa EH, da Silva MA, Alves TM, Louzã MR, Pompéia S, et al. Mindfulness meditation improves mood, quality of life, and attention in adults with attention deficit hyperactivity disorder. Biomed Res Int. 2015;2015:962857. https://doi.org/10.1155/2015/962857 
  106. Hesslinger B, Tebartz van Elst L, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults: A pilot study using a structured skills training programme. Eur Arch Psychiatry Clin Neurosci. 2002;252:177–184. https://doi.org/10.1007/s00406-002-0379-0
  107. Wiggens D, Singh K, Getz HG, Hutchins DE. Effects of brief group intervention for adults with attention deficit/hyperactivity disorder. J Ment Health Couns. 1999;21:82–92.
  108. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ. A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 2002;36:610–616. https://doi. org/10.1046/j.1440-1614.2002.01052.x
  109. Ratey JJ, Greenberg MS, Bemporad JR, Lindem KJ. Unrecognized attentiondeficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol. 1992;2:267–275. https://doi.org/10.1089/ cap.1992.2.267
  110. Arns M, Heinrich H, Strehl U. Evaluation of neurofeedback in ADHD: The long and winding road. Biol Psychol. 2014;95:108–115. https://doi.org/10.1016/j. biopsycho.2013.11.013
  111. Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of neurofeedback treatment in ADHD: The effects on inattention, impulsivity and hyperactivity: A meta-analysis. Clin EEG Neurosci. 2009;40:180–189. https://doi. org/10.1177/155005940904000311
  112. Mayer K, Blume F, Wyckoff SN, Brokmeier LL, Strehl U. Neurofeedback of slow cortical potentials as a treatment for adults with Attention Deficit-/Hyperactivity Disorder. Clin Neurophysiol. 2016;127(2):1374–1386. https://doi.org/10.1016/j. clinph.2015.11.013
  113. Sonuga-Barke EJS, Brandeis D, Cortese S, et al. Non-pharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry. 2013;170(3):275–289. https://doi.org/10.1176/appi.ajp.2012.12070991
  114. Lambourne K, Tomporowski P. The effect of exercise-induced arousal on cognitive task performance: A meta-regression analysis. Brain Res. 2010;1341:12–24. https://doi.org/10.1016/j.brainres.2010.03.091
  115. Randolph J. Lifestyle factors and ADHD: The positive role of physical activity. Natl Acad Neuropsychol Bull. 2015;30(1):14–15.
  116. Gapin JI, Etnier JL. The relationship between physical activity and executive function performance in children with attention deficit hyperactivity disorder. J Sport Exerc Psychol. 2010;32:753–763. https://doi.org/10.1123/jsep.32.6.753
  117. Chang Y-K, Liu S, Yu H-H, Lee Y-H. Effect of acute exercise on executive function in children with Attention Deficit Hyperactivity Disorder. Arch Clin Neuropsychol. 2012;27:225–237. https://doi.org/10.1093/arclin/acr094
  118. Piepmeier AT, Shih C-H, Whedon M, et al. The effect of acute exercise on cognitive performance in children with and without ADHD. J Sport Health Sci. 2015;4:97–104. https://doi.org/10.1016/j.jshs.2014.11.004 
  119. Pontifex MB, Saliba BJ, Raine LB, Picchietti DL, Hillman CH. Exercise improves behavioural, neurocognitive, and scholastic performance in children with Attention-Deficit/Hyperactivity Disorder. J Paediatr. 2013;62:543–551. https:// doi.org/10.1016/j.jpeds.2012.08.036
  120. Medina JA, Netto LB, Muszkat M, et al. Exercise impact on sustained attention of ADHD children, methylphenidate effects. Atten Defic Hyperact Disord. 2010;2:49–58. https://doi.org/10.1007/s12402-009-0018-y
  121. Halperine JM, Healey DM. The influences of environmental enrichment, cognitive enhancement, and physical exercise on brain development: Can we alter the developmental trajectory of ADHD? Neurosci Biobehav Rev. 2011;35(3):621–634. https://doi.org/10.1016/j.neubiorev.2010.07.006
  122. Jones GJ. Acute exercise and executive function in young adults with ADHD. Dissertation in fulfilment for the degree Doctor of Philosophy. University of Iowa; 2015 [cited 2015 July 7]. Available from http://ir.uiowa.edu/etd/1651
  123. Neudecker C, Mewes N, Reimers AK, Woll A. Exercise interventions in children and adolescents with ADHD: A systematic review. J Atten Disord. 2015:1–18. https://doi.org/10.1177/1087054715584053
  124. Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P. Omega-3 poly-unsaturated fatty acid supplementation and cognition: A systematic review and metaanalysis. J Psychopharmacol. 2015;29(7):753–763. https://doi.org/10.1177/ 0269881115587958
  125. Bazire S. Pscyhotropic drug directory 2012. The professionals pocket handbook and Aide Memoire. Cheltenham: Lloyd-Reinhold Communications; 2012.

Click here for the pdf

 Schoeman R, Liebenberg R. The South African Society of Psychiatrists/Psychiatry Management Group Management Guidelines for Adult Attention-Deficit/ Hyperactivity Disorder. S Afr J Psychiat. 2017;23(0), a1060. https://doi.org/10.4102/sajpsychiatry.v23i0.1060 - An Update on the ADHD Treatment Armamentarium in South Africa., Prof Renata Schoeman

South African Journal of Psychiatry; The South African Society of Psychiatrists/Psychiatry Management Group the Management Guidelines for Adult Attention-Deficit/ Hyperactivity Disorder, 28 April 2017_An Update on the ADHD Treatment Armamentarium in South Africa, 2023

Drugs mentioned

NeoHealth® ID 17291 · updated 7/4/2024